| 期刊論文1. | Shen, Winston W.(1999)。A history of antipsychotic drug development。Comprehensive Psychiatry,40(6),407-414。 | 2. | 白雅美(20120300)。Pharmacological Studies on Patients with Schizophrenia in Taiwan: A Compilation of Literature。Taiwanese Journal of Psychiatry,26(1),6-18+66。 | 3. | Hong, C. J.、Chen, J. Y.、Chiu, H. J.(1997)。A double-blind. Comparative study of clozapine versus chlorpromazine on Chinese patients with treatment - refractory schizophrenia。Int Clin Psychopharmacol,12,123-130。 | 4. | Chen, C. H.、Lee, C. S.、Lee, M. T. M.、Ouyang, W. C.、Chen, C. C.、Chong, M. Y.、Cheng, A. T. A.(2014)。Variant GADL1 and response to lithium therapy in bipolar I disorder。The New England Journal of Medicine,370(2),119-128。 | 5. | Chung, Wen-Hung、Hung, Shuen-Iu、Hong, Hong-Shang、Hsih, Mo-Song、Yang, Li-Cheng、Ho, Hsin-Chun、Wu, Jer-Yuarn、Chen, Yuan-Tsong(2004)。Medical Genetics: A Marker for Stevens-Johnson Syndrome。Nature,428(6982)。 | 6. | Umbricht, D.、Alberati, D.、Martin-Facklam, M.(2014)。Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study。JAMA Psychiatry,71,637-646。 | 7. | Sabbatini, R. M. E.(1997)。The history of shock therapy in psychiatry。Brain and Mind,4。 | 8. | Dax, E. C.、Freudenberg, R. K.(1948)。Prefrontal leucotomy, a review。Postgrad Med J,24,415-426。 | 9. | Shorter, E.(2011)。A brief history of placebos and clinical trials in psychiatry。Can J Psychiatry,56,193-197。 | 10. | Kopeloff, N.、Cheney, C. O.(1922)。Studies in focal infection: its presence and elimination in the functional psychoses。Am J Psychiatry,79,139-156。 | 11. | Prinzmetal, M.、Bloomberg, W.(1935)。The use of Benzedrine for the treatment of narcolepsy。JAMA,105。 | 12. | Ban, T. A.(2007)。Fifty years chlorpromazine: a historical perspective。Neuropsychiatr Dis Treat,3,495-500。 | 13. | Lopez-Munoz, F.、Shen, W. W.、Alamo, C.、Cacabelos, R.、Lai, T. J.(2014)。Serendipitous discovery of first two antide pressants。Taiwaneses Journal of Psychiatry,28,70。 | 14. | Huttunen, M.(1995)。The evolution of the serotonin-dopa mine antagonist concept。J Clin Psychopharmacol,15 (1 Suppl 1),4-10。 | 15. | Miller, F. G.(2000)。Placebo-controlled trials in psychiatric research: an ethical perspective。Biol Psychiatry,47,707-716。 | 16. | Deeks, E. D.、Keating, G. M.(2010)。Blonanserin: a review of its use in the management of schizophrenia。CNS Drugs,24,65-84。 | 17. | Bruijnzeel, D.、Yazdanpanah, M.、Suryadevara, U.、Tandon, R.(2015)。Lurasidone in the treatment of schizophrenia: a critical evaluation。Exp Opin Pharmacother,16,1559-1565。 | 18. | Citrome, L.(2011)。Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly ap proved second-generation antipsychotic。Int J Clin Pract,65,189-210。 | 19. | Rajagopalan, K.、Trueman, D.、Crowe, L.、Squirrell, D.、Loebel, A.(2016)。Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia。Pharmacoeconomics,34(7),709-721。 | 20. | Maeda, K.、Lerdrup, L.、Sugino, H.(2014)。Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator。J Pharmacol Exp Ther,350,605-614。 | 21. | Stahl, S. M.(2016)。Mechanism of action of brexpiprazole: comparison with aripiprazole。CNS Spectr,21,1-6。 | 22. | McKeage, K.(2016)。Adjunctive brexpiprazole: a review in major depressive disorder。CNS Drugs,30,91-99。 | 23. | Grunder, G.(2010)。Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression。Curr Opin Investig Drugs,11,823-832。 | 24. | Durgam, S.、Cutler, A. J.、Lu, K.(2015)。Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial。J Clin Psychiatry,76,e1574- e1582。 | 25. | Vieta, E.、Durgam, S.、Lu, K.(2015)。Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials。Eur Neuropsychopharmacol,25,1882-1891。 | 26. | Durgam, S.、Earley, W.、Lipschitz, A.(2016)。An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression。Am J Psychiatry,173,271-281。 | 27. | Tenjin, T.、Miyamoto, S.、Ninomiya, Y.(2013)。Profile of blonanserin for the treatment of schizophrenia。Neuropsychiatr Dis Treat,9,587-594。 | 28. | Garcia, E.、Robert, M.、Peris, F.(2009)。The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double blind, placebo-controlled, multicentre study。CNS Drugs,23,615-625。 | 29. | Adams, D. H.、Kinon, B. J.、Baygani, S.(2013)。A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsy chotic standard of care in patients with schizophre nia。BMC Psychiatry,13。 | 30. | Bugarski-Kirola, D.、Wang, A.、Abi-Saab, D.、Blattler, T.(2014)。A phase II/III trial of bitopertin monotherapy com pared with placebo in patients with an acute exacer bation of schizophrenia - results from the CandleLyte study。Eur Neuropsychopharmacol,24,1024-1036。 | 31. | Kinon, B. J.、Millen, B. A.、Zhang, L.、McKinzie, D. L.(2015)。Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 recep tor agonist pomaglumetad methionil in schizophre nia。Biol Psychiatry,78,754-762。 | 32. | Hwu, H. G.(1995)。Therapeutic effect of Buspirone and lorazepam in generalized anxiety disorder patients。Taiwanese Journal of Psychiatry,9,310-318。 | 33. | Lin, S. K.、Strang, J.、Su, L. W.、Tsai, C. J.、Hu, W. H.(1997)。Double blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal。Drug Alcohol Depend,48,127-133。 | 34. | 黃宗正、林世光、林信男(20011200)。Efficacy and Safety of Zotepine for the Treatment of Taiwanese Schizophrenic Patients: A Double-Blind Comparison with Haloperidol。臺灣醫學會雜誌,100(12),811-816。 | 35. | Hwang, T. J.、Lee, S. M.、Sun, H. J.(2003)。Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan。J Formos Med Assoc,102,30-36。 | 36. | Gau, S. S.、Huang, Y. S.、Soong, W. T.(2007)。A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity dis order。J Child Adolesc Psychopharmacol,17,447-460。 | 37. | Chang, T. T.、Leng, C. H.、Wu, J. Y.(2008)。Fewer side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan。Chin J Physiol,51,387-393。 | 38. | López-Muñoz, Francisco、沈武典、Moreno, Raquel、Molina, Juan D.、Noriega, Concha、Pérez-Nieto, Miguel A.、Rubio, Gabriel、Álamo, Cecilio(20120600)。International Scientific Productivity on Second-generation Antipsychotic Drugs in Taiwan: A Bibliometric Study。Taiwanese Journal of Psychiatry,26(2),114-129+146。 | 39. | Lane, H. Y.、Chang, Y. C.、Liu, Y. C.、Chiu, C. C.、Tsai, G. E.(2005)。Sarcosine or D-serine add-on treatment for acute ex acerbation of schizophrenia: a randomized, double blind, placebo-controlled study。Arch Gen Psychiatry,62,1196-1204。 | 40. | Lin, S. K.、Chen, C. H.、Pan, C. H.(2008)。Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial。J Clin Psychopharmacol,28,189-194。 | 41. | Lin, S. K.、Pan, C. H.、Chen, C. H.(2014)。A double-blind, placebo controlled trial of dextromethorphan combined with clonidine in the treatment of heroin withdrawal。J Clin Psychopharmacol,34,508-512。 | 42. | Lee, S. Y.、Chen, S. L.、Chang, Y. H.(2015)。A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment。International Journal of Neuropsychopharmacology,18(7),1-8。 | 43. | Chang, Y. H.、Chen, S. L.、Lee, S. Y.(2015)。Low-dose add on memantine treatment may improve cognitive performance and self-reported health conditions in opi oid-dependent patients undergoing methadone maintenance-therapy。Sci Rep,5。 | 44. | Lee, S. Y.、Chen, S. L.、Chang, Y. H.(2015)。Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial。Sci Rep,5。 | 45. | Kitchen, H.、Rofail, D.、Heron, L.、Sacco, P.(2012)。Cognitive impairment associated with schizophrenia: a review of the humanistic burden。Adv Ther,29,148-162。 | 46. | Garay, R. P.、Citrome, L.、Samalin, L.(2016)。Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries。Expert Opin Pharmacother,17,921-936。 | 47. | Snyder, G. L.、Vanover, K. E.、Zhu, H.(2015)。Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission。Psychopharmac ology,232,605-621。 | 48. | Lieberman, J. A.、Davis, R. E.、Correll, C. U.(2015)。ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial。Biol Psychiatry,79(12),952-961。 | 49. | Hacksell, U.、Burstein, E. S.、McFarland, K.、Mills, R. G.、Williams, H.(2014)。On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis。Neurochem Res,39,2008-2017。 | 50. | Parra, S.、Bond, R. A.(2007)。Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?。Curr Opin Pharmacol,7,146-150。 | 51. | Cummings, J.、Isaacson, S.、Mills, R.(2014)。Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial。Lancet,383,533-540。 | 52. | Garay, R. P.、Bourin, M.、de Paillette, E.(2016)。Potential serotonergic agents for the treatment of schizophrenia。Expert Opin Investig Drugs,25,159-170。 | 53. | Essayan, D. M.(2001)。Cyclic nucleotide phosphodiesterases。J Allergy Clin Immunol,108,671-680。 | 54. | Bruzziches, R.、Francomano, D.、Gareri, P.、Lenzi, A.、Aversa, A.(2013)。An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors。Expert Opin Pharmacother,14,1333-1344。 | 55. | Chrysant, S. G.(2013)。Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension。Curr Hypertens Rep,15,475-483。 | 56. | Goff, D. C.、Cather, C.、Freudenreich, O.(2009)。A place bo-controlled study of sildenafil effects on cognition in schizophrenia。Psychopharmacology,202,411-417。 | 57. | Li, P.、Zheng, H.、Zhao, J.(2016)。Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases。J Med Chem,59,1149-1164。 | 58. | Adler, L. E.、Olincy, A.、Waldo, M.(1998)。Schizophrenia, sensory gating, and nicotinic receptors。Schizophr Bull,24,189-202。 | 59. | Keefe, R. S.、Meltzer, H. A.、Dgetluck, N.(2015)。Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine re ceptor agonist, as a treatment for cognitive impair ment in schizophrenia。Neuropsychopharmacology,40,3053-3060。 | 60. | Feuerbach, D.、Pezous, N.、Weiss, M.(2015)。AQW051, a novel, potent and selective alpha7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation。Br J Pharmacol,172,1292-1304。 | 61. | Umbricht, D.、Keefe, R. S.、Murray, S.(2014)。A randomized, placebo-controlled study investigating the nicotinic alpha 7 agonist, RG3487, for cognitive deficits in schizophrenia。Neuropsychopharmacology,39,1568-1577。 | 62. | Volpi, S.、Potkin, S. G.、Malhotra, A. K.、Licamele, L.、Lavedan, C.(2009)。Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia。J Clin Psychiatry,70,801-809。 | 63. | Malan-Muller, S.、Kilian, S.、van den Heuvel, L. L.(2016)。A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia。Schizophr Res,170,1-17。 | 64. | López-Muñoz, Francisco、Alamo, Cecilio、Cuenca, Eduardo、Shen, Winston W.、Clervoy, Patrick、Rubio, Gabriel(2005)。History of the discovery and clinical introduction of chlorpromazine。Annals of Clinical Psychiatry,17(3),113-135。 | 65. | Chan, H. Y.、Lin, W. W.、Lin, S. K.(2007)。Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial。J Clin Psychiatry,68,29-36。 | 66. | Chen, C. H.、Chiu, C. C.、Huang, M. C.、Wu, T. H.、Liu, H. C.、Lu, M. L.(2008)。Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine。Prog Neuropsychopharmacol Biol Psychiatry,32,925-931。 | 67. | Lane, H. Y.、Lin, C. H.、Huang, Y. J.、Liao, C. H.、Chang, Y. C.、Tsai, G. E.(2010)。A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia。The International Journal of Neuropsychopharmacol,13(4),451-460。 | |
| |